Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-3280 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: GDC-3280 | EXPERIMENTAL | Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions. |
| Part B: GCD-3280 | EXPERIMENTAL | Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\\n |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\\n |
| Name | Type | Description |
|---|---|---|
| GDC-3280 | DRUG | GDC-3280 at various doses, depending on the cohort and treatment period |
| Placebo | DRUG | Placebo at various doses, depending on the cohort and treatment period |
Inclusion Criteria: * Is male or female, using highly effective contraception * Has a body mass index (BMI) 18.0 to 30.0 kg/m2, inclusive * Is in good general health * Having signed informed consent, is willing and able to comply with requirements of the study Exclusion Criteria: * Does not satis...
GDC-3280 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United Kingdom. The specific disease indications for GDC-3280 have not been disclosed.
GDC-3280 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche conducted the Phase 1 study of GDC-3280 in healthy participants.
GDC-3280 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study enrolled 8 healthy volunteers and was conducted in the United Kingdom.
GDC-3280 has been evaluated in one clinical trial, NCT02471859, titled A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants. The Phase 1 trial was completed, enrolled 8 participants, and was conducted in the United Kingdom.
GDC-3280 is not approved. It is an investigational small molecule in Phase 1 clinical development, and the only listed trial, NCT02471859, has been completed. No regulatory approval has been granted for GDC-3280.
The GDC-3280 Phase 1 trial, NCT02471859, was a randomized, double-blind, placebo-controlled study in healthy volunteers. It enrolled 8 participants aged 18 years and older of all sexes in the United Kingdom, and assessed safety, tolerability, and pharmacokinetics.